Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update

Fineline Cube Dec 22, 2023

GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...

Company Drug

Takeda’s Livtencity Receives NMPA Approval, a First in China for CMV Infection Treatment

Fineline Cube Dec 22, 2023

Japanese pharmaceutical company Takeda (TYO: 4502) has received its first market approval from China’s National...

Company Deals

China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary

Fineline Cube Dec 22, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Medical Device

Beijing Balance Medical Secures NMPA Approval for Innovative Mitral Valve Annuloplasty Ring

Fineline Cube Dec 22, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a Chinese medical device company, has received...

Company Deals

Beijing Strong Biotechnologies Strikes Distribution Deal with ELITechGroup for Immunohistochemical Staining Systems

Fineline Cube Dec 22, 2023

Beijing Strong Biotechnologies Inc., (SHE: 300406) a Chinese company, has entered into a product distribution...

Company Deals

Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program

Fineline Cube Dec 22, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug...

Company Drug

AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer

Fineline Cube Dec 21, 2023

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III...

Company Drug

Lee’s Pharmaceutical’s Socazolimab Becomes China’s First PD-L1 mAb for Cervical Cancer

Fineline Cube Dec 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for...

Company Deals

Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms

Fineline Cube Dec 21, 2023

Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG:...

Company Drug

FDA Rejects MSD’s Gefapixant for Chronic Cough Treatment Over Efficacy Concerns

Fineline Cube Dec 21, 2023

The US Food and Drug Administration (FDA) has declined to approve a filing from Merck,...

Company Deals

Shanghai Novopathway and PONY Biomedicine Join Forces for Pre-Clinical Drug Development Platform

Fineline Cube Dec 21, 2023

Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow...

Company Deals

GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal

Fineline Cube Dec 21, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing...

Company Deals

3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension

Fineline Cube Dec 21, 2023

3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a...

Company Medical Device

Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany

Fineline Cube Dec 21, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates

Fineline Cube Dec 21, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Drug

RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome

Fineline Cube Dec 21, 2023

RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...

Company

Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines

Fineline Cube Dec 21, 2023

Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an...

Company Deals

LianBio Board Turns Down Concentra Biosciences Buyout Offer

Fineline Cube Dec 20, 2023

China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...

Company Deals

Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal

Fineline Cube Dec 20, 2023

Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...

Company Deals

Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement

Fineline Cube Dec 20, 2023

China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...

Posts pagination

1 … 362 363 364 … 602

Recent updates

  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.